RT Journal Article SR Electronic T1 Functional Comparison of Different Exome Capture-based Methods for Transcriptomic Profiling of Formalin-Fixed Paraffin-Embedded Tumor Samples JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.24.21250395 DO 10.1101/2021.01.24.21250395 A1 Kyrillus S. Shohdy A1 Rohan Bareja A1 Michael Sigouros A1 David C. Wilkes A1 Princesca Dorsaint A1 Jyothi Manohar A1 Daniel Bockelman A1 Jenny Z. Xiang A1 Rob Kim A1 Juan Miguel Mosquera A1 Olivier Elemento A1 Andrea Sboner A1 Alicia Alonso A1 Bishoy M. Faltas YR 2021 UL http://medrxiv.org/content/early/2021/01/25/2021.01.24.21250395.abstract AB Background The need for fresh frozen (FF) tissue limits implementing RNA sequencing (RNA-seq) in the clinic. The majority of clinical samples are processed in clinical laboratories and stored as formalin-fixed, paraffin-embedded (FFPE) tissues. Exome capture has recently emerged as a promising approach for RNA-seq from FFPE samples. Multiple exome capture platforms are now available. However, their performances have not been systematically compared.Methods Transcriptomic analysis of 32 FFPE tumor samples from 11 patients was performed using three exome capture-based methods: Agilent SureSelect V6, TWIST NGS Exome, and IDT XGen Exome Research Panel. We compared these methods to TruSeq RNA-seq of fresh frozen (FF-TruSeq) tumor samples from the same patients. We assessed the recovery of clinically relevant biological features, including the expression of key immune genes, expression outliers often associated with actionable genes, gene expression-based subtypes, and fusions using each of these capture methods.Results The Spearman’s correlation coefficients between global expression profiles of the three capture-based methods and matched FF tumor samples, analyzed using TruSeq RNA-seq, were high (rho = 0.72-0.9, p < 0.05). There was a significant correlation between the expression of key immune genes between individual capture-based methods and FF-TruSeq (rho = 0.76-0.88, p < 0.05). All three exome capture-based methods reliably detected the outlier expression of actionable genes, including ERBB2, MET, NTRK1, and PPARG, initially detected in FF-TruSeq. In urothelial cancer samples, the Agilent assay was associated with the highest molecular subtyping agreement with FF-TruSeq (Cohen’s k = 0.7, p < 0.01). Both Agilent and IDT detected all the clinically relevant fusions which were initially identified in FF-TruSeq.Conclusion All exome capture-based methods had comparable performance and concordance with FF-TruSeq. These findings provide a path for the transcriptomic profiling of vast numbers of FFPE currently stored in biobanks. For specific applications such as fusion detection and gene expression-based subtyping, some methods performed better. By enabling the interrogation of FFPE tumor samples, our findings open the door for implementing RNA-seq in the clinic to guide precision oncology approaches.Competing Interest StatementCompeting interests B.M.F. has received research support for Weill Cornell from Eli Lilly and served on advisory boards for Immunomedics and Merck & Co. Funding StatementBMF was supported by the Department of Defense CDMRP grant CA160212. This work was also supported by a Conquer Cancer Foundation Long Term International Fellowship Award (KSS) and the Englander Institute for Precision Medicine at WCM (OE, AS, BMF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:(Weill Cornell IRB #1305013903).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw RNA-seq datasets analyzed during the current study are available from the corresponding author on reasonable request.